Palla Pharma Ltd
ASX:PAL

Watchlist Manager
Palla Pharma Ltd Logo
Palla Pharma Ltd
ASX:PAL
Watchlist
Price: 0.295 AUD Market Closed
Market Cap: AU$47.8m

PAL's latest stock split occurred on Mar 2, 2021

The company executed a 1283-for-1220 stock split, meaning that for every 1220 shares held, investors received 1283 new shares.

Before the split, PAL traded at 0.6514 per share. Afterward, the share price was about 0.6.

The adjusted shares began trading on Mar 2, 2021. This was PAL's 3rd stock split, following the previous one in Oct 21, 2019.

Last Splits:
Mar 2, 2021
1283-for-1220
Oct 21, 2019
63-for-59
Mar 27, 2017
72-for-71
Pre-Split Price
0.6514 0.6514
Post-Split Price
0.6
Before
After
Last Splits:
Mar 2, 2021
1283-for-1220
Oct 21, 2019
63-for-59
Mar 27, 2017
72-for-71

Palla Pharma Ltd
Stock Splits History

PAL Stock Splits Timeline
Mar 2, 2021
Mar 2, 2021
Split 1283-for-1220
x1.0516393442623
Pre-Split Price
0.6514 0.6514
Post-Split Price
0.6
Before
After
Oct 21, 2019
Oct 21, 2019
Split 63-for-59
x1.0677966101695
Pre-Split Price
0.8429 0.9
Post-Split Price
0.86
Before
After
Mar 27, 2017
Mar 27, 2017
Split 72-for-71
x1.0140845070423
Pre-Split Price
2.2164 2.4
Post-Split Price
2.1352
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 22, 2026
Chimeric Therapeutics Ltd
ASX:CHM
1-for-100
/100
0.002 0.2 AUD 0.17 0.17 AUD
Apr 22, 2026
Architects Studio Japan Inc
TSE:6085
10-for-1
x10
3800 380 JPY 430 430 JPY
Apr 22, 2026
Freewon China Co Ltd
SSE:688678
1-for-1
x1
30.5 21.6857 CNY 23.64 23.64 CNY
Apr 22, 2026
S
Sharetronic Data Technology Co Ltd
SZSE:300857
1-for-1
x1
304.5701 217.2101 CNY 260.76 260.76 CNY
Apr 21, 2026
Canon Electronics Inc
OTC:CAOEF
1-for-6235122
/6235122
16.96 16.96 USD N/A
Load More

Palla Pharma Ltd
Glance View

Palla Pharma Ltd. manufactures and produces narcotic raw material for the international pharmaceutical industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-13. The firm's primary activities include production and distribution of Narcotic Raw Material (NRM),Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF) for supply to international pharmaceutical markets, and the production and distribution of poppy seed for supply to international culinary markets. The firm operates through two segments: Australia and Norway. Australia segment activities include Narcotic Raw Material and Poppy Seed production and distribution. Norway segment activities include Active Pharmaceutical Ingredient and Finished Dosage production and distribution. The firm has developed a water-based extraction technology, which is used in NRM production. The company sources its raw materials from Australian poppy growers in Tasmania, New South Wales, and Victoria.

PAL Intrinsic Value
Not Available
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett